Posted by Michael Wonder on 02 Feb 2023
Enhertu launched as gastric cancer tertiary treatment in Korea, insurance benefits loading
2 February 2023 - In an environment where gastric cancer treatments are currently lacking, the approval of Enhertu (ingredient: trastuzumab deruxtecan) as a tertiary treatment for HER2-positive gastric cancer represents a major milestone for gastric cancer patients, said an expert.
Commenting on the insurance coverage for this drug, an official from Daiichi Sankyo Korea said, "In December last year, we completed the application for insurance reimbursement for breast cancer and gastric cancer together and are currently awaiting a response from the Health Insurance Review Assessment (HIRA)."
